Monday, March 20, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Partnerships for Diagnostics to Address Antimicrobial Resistance

by Global Biodefense Staff
March 14, 2014

The National Institutes of Health is soliciting research applications for projects focused on development of diagnostics that will enable rapid, sensitive, specific, culture-independent detection of high-priority antimicrobial-resistant Gram-negative bacterial pathogens.

The effort is focused on select healthcare-associated bacteria where resistance compromises effective treatment, including: Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and extra-intestinal pathogenic Escherichia coli.

Development of rapid and informative diagnostics will help clinicians to quickly determine the most effective treatment for infected individuals and will facilitate antimicrobial stewardship by reducing the empiric use of broad-spectrum antimicrobials.  Additionally, such diagnostics would benefit development and approval of new antibacterials by reducing the diagnostic uncertainty that necessitates enrollment of large numbers of patients who may not be evaluable in pivotal efficacy trials. Hence, rapid diagnostics should provide a means to reduce the size and cost of antibacterial clinical trials.

The proposed diagnostic must be designed to detect the target pathogens in normally sterile sample types such as blood, cerebral spinal fluid and pleural fluid.  The diagnostic may also include the detection of the target pathogens in the context of non-sterile sample types, such as for hospital- or ventilator-associated pneumonia. The proposed platforms must be supported by proof-of-concept data demonstrating feasibility. Examples of research areas supported include:

  • Assay or prototype development
  • Sample preparation
  • Development of broad-spectrum platforms or production technologies
  • Adaptation of products or platform technologies to new applications
  • Optimization of products or technologies
  • Process development
  • Diagnostic validation

Applications must include a Product Development Strategy and demonstrate substantive participation by at least one industrial participant.

Further details are available under RFA-AI-14-019.

Tags: AntimicrobialsE. coli

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.
Policy + Initiatives

Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.

December 7, 2022
Study: Cash Incentives and Lotteries Do Little to Increase Adult Vaccinations
Medical Countermeasures

Study: Cash Incentives and Lotteries Do Little to Increase Adult Vaccinations

October 25, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC